在患有病毒性下呼吸道疾病的患者中,IL-33与膜功能障碍有关
Ian C Scott1, Natalie van Zuydam2, Jennifer A Cann3
1Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
在病毒性下呼吸道疾病期间释放的介素-33 (IL-33) 与严重的结果相关. 气道和血液循环中IL-33及其复合物的升高表明预后不佳和潜在的气膜功能障碍.
科学领域:
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 介素-33 (IL-33) 涉及到呼吸道炎症和重塑.
- 它在病毒性下呼吸道疾病 (LRTD) 病原发生中的作用尚未完全理解.
研究的目的:
- 研究IL-33与COVID-19住院患者的临床结果和病理机制的关联.
- 描述IL-33及其受体在肺组织中的表达和定位.
主要方法:
- 开发超灵敏免疫测试以量化IL-33,氧化IL-33 (IL-33ox) 和IL-33/sST2复合体.
- 使用免疫组织化学和多组学来分析肺组织样本.
- 在体外内皮细胞培养实验中评估IL-33对炎症介质的影响.
主要成果:
- 呼吸道中的IL-33和循环中的IL-33/sST2复合物的增加与不良的临床结果相关,包括死亡和需要机械通风.
- IL-33局部存在于气道上皮和内皮屏障,IL1RL1在气泡细胞上表达.
- 暴露于IL-33增加了中性友炎的媒介体的表达,免疫细胞的透,干扰素信号传递和内皮细胞的凝血.
结论:
- 病毒LRTD中IL-33释放的增加与不良临床结果有关.
- IL-33可能会导致病毒LRTD的膜功能障碍和病理.
- 需要进一步的研究来评估IL-33在病毒LRTD中的病理作用.
更多相关视频
06:29Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
09:02Infection of Primary Nasal Epithelial Cells Grown at an Air-Liquid Interface to Characterize Human Coronavirus-Host Interactions
Published on: September 22, 2023
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
